Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes

The safety and effectiveness of automated glycemic management have not been tested in multiday studies under unrestricted outpatient conditions.

In two random-order, crossover studies with similar but distinct designs, we compared glycemic control with a wearable, bihormonal, automated, "bionic" pancreas (bionic-pancreas period) with glycemic control with an insulin pump (control period) for 5 days in 20 adults and 32 adolescents with type 1 diabetes mellitus. The automatically adaptive algorithm of the bionic pancreas received data from a continuous glucose monitor to control subcutaneous delivery of insulin and glucagon.